Core Insights - Cullen Capital Management's "SCCM Value Equity Strategy" reported a gross return of 6.9% and a net return of 6.8% for Q3 2025, outperforming the Russell 1000 Value's 5.3% and underperforming the S&P 500's 8.1% during the same period [1] - Year-to-date, the strategy achieved a gross return of 13.0%, compared to Russell 1000 Value's 11.7% and S&P 500's 14.8% [1] Company Overview - Becton, Dickinson and Company (NYSE: BDX) is a global medical technology company that develops and manufactures a wide range of medical supplies, devices, laboratory equipment, and diagnostic products [2][3] - The company has three main segments: BD Medical (50% of 2024 sales), BD Life Sciences (26%), and BD Interventional (24%) [3] - BD Medical focuses on medication delivery devices, holding over 80% market share in US hospital syringes, making it the largest manufacturer of syringes globally [3] Stock Performance - Becton, Dickinson and Company's stock had a one-month return of 2.24% but lost 13.52% over the last 52 weeks, closing at $192.33 per share on November 18, 2025, with a market capitalization of $55.127 billion [2]